Pituitary Tumors Clinical Trial
Official title:
Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary
DNA methylation is one of the important ways of protein post-translational modification.Pituitary adenoma (PA) is a benign neuroendocrine tumor that originates from adenohypophysial 45 cells, and accounts for 10%-20% of all primary intracranial tumors. However some PAs can present with high invasiveness and irregular growth, which tend to compresses the optic chiasm and third ventricle, encase the internal carotid artery, and affect hormone secretion from the pituitary gland and hypothalamus. In this study we focus on the mechanism of DNA methylation on the invasiveness of pituitary tumors.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01903967 -
Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)
|
N/A | |
Completed |
NCT01689727 -
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
|
Phase 2 | |
Completed |
NCT01322945 -
Barrow Nasal Inventory Survey
|
N/A | |
Completed |
NCT00565903 -
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
|
||
Completed |
NCT01794793 -
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
|
Phase 4 | |
Completed |
NCT00462475 -
Effect of 5 Years of GH Replacement on Atherosclerosis
|
Phase 4 |